• 1. 75. Derivatives of 6-aminopenicillanic acid. Part IV. Analogues of 2,6-dimethoxyphenylpenicillin in the naphthalene and quinoline series
  E. G. Brain,F. P. Doyle,M. D. Mehta,D. Miller,J. H. C. Nayler,E. R. Stove J. Chem. Soc. 1963 491
• 2. Index of authors' names
  J. Chem. Soc. Abstr. 1924 126 ii877
• 3. Magnesium complexes containing bis-amido-oxazolinate ligands as efficient catalysts for ring opening polymerisation of l-lactide
  Ming-Tsz Chen,Ping-Jung Chang,Chi-An Huang,Kuo-Fu Peng,Chi-Tien Chen l-lactide. Ming-Tsz Chen Ping-Jung Chang Chi-An Huang Kuo-Fu Peng Chi-Tien Chen Dalton Trans. 2009 9068
• 4. A proton magnetic resonance investigation of the structure of urea
  E. R. Andrew,D. Hyndman Discuss. Faraday Soc. 1955 19 195
• 5. Nitrile functionalised pendant-arm derivatives of aza- and mixed donor macrocyclic ligands as new building blocks for inorganic crystal engineering
  Lorenzo Tei,Alexander J. Blake,Paul A. Cooke,Claudia Caltagirone,Francesco Demartin,Vito Lippolis,Francesca Morale,Claire Wilson,Martin Schr?der J. Chem. Soc. Dalton Trans. 2002 1662

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Quinoline carboxylic acids
• Pharmaceutical and Biochemical Products Pharmaceutical Intermediates

Recent Advances in the Study of 3-Hydroxyquinoline-4-carboxylic acid (CAS 118-13-8): A Comprehensive Research Brief

3-Hydroxyquinoline-4-carboxylic acid (CAS 118-13-8) is a quinoline derivative that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its versatile pharmacological properties. Recent studies have explored its potential as a scaffold for drug development, particularly in the areas of antimicrobial, anti-inflammatory, and anticancer therapies. This research brief synthesizes the latest findings on this compound, highlighting its molecular mechanisms, synthetic pathways, and therapeutic applications.

A 2023 study published in the Journal of Medicinal Chemistry investigated the antimicrobial efficacy of 3-Hydroxyquinoline-4-carboxylic acid against multidrug-resistant bacterial strains. The researchers employed a combination of in vitro assays and molecular docking simulations to demonstrate that this compound exhibits potent inhibitory activity against key bacterial enzymes, such as DNA gyrase and topoisomerase IV. These findings suggest its potential as a lead compound for developing novel antibiotics to combat antimicrobial resistance.

In the context of anticancer research, a recent paper in Bioorganic & Medicinal Chemistry Letters (2024) reported that 3-Hydroxyquinoline-4-carboxylic acid derivatives show promising activity against various cancer cell lines, including breast and lung carcinomas. The study utilized structure-activity relationship (SAR) analysis to optimize the compound's efficacy, identifying specific modifications that enhance its cytotoxicity while minimizing off-target effects. These results underscore the compound's potential as a versatile scaffold for designing targeted cancer therapies.

The synthetic pathways for 3-Hydroxyquinoline-4-carboxylic acid have also seen advancements. A 2023 publication in Organic Process Research & Development detailed a novel, scalable synthesis method that improves yield and reduces environmental impact. This method employs green chemistry principles, such as catalytic hydrogenation and solvent-free reactions, making it more sustainable for industrial-scale production. Such innovations are critical for facilitating the transition from laboratory research to clinical applications.

Despite these promising developments, challenges remain in the clinical translation of 3-Hydroxyquinoline-4-carboxylic acid-based therapies. Pharmacokinetic studies, as highlighted in a 2024 review in Expert Opinion on Drug Metabolism & Toxicology, indicate that the compound's bioavailability and metabolic stability require further optimization. Researchers are exploring prodrug strategies and nanoformulations to address these limitations, aiming to enhance its therapeutic index.

In conclusion, 3-Hydroxyquinoline-4-carboxylic acid (CAS 118-13-8) represents a compelling area of research in chemical biology and drug discovery. Its multifaceted pharmacological properties, coupled with recent advancements in synthesis and optimization, position it as a valuable candidate for future therapeutic development. Ongoing studies are expected to further elucidate its mechanisms of action and expand its clinical potential, offering new avenues for treating challenging diseases.

• 55698-67-4(8-hydroxyquinoline-4-carboxylic acid)
• 73776-18-8(methyl 3-hydroxyquinoline-4-carboxylate)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)